Lenalidomide versus Thalidomide or Bortezomib as maintenance regimen for non-transplant patients with multiple myeloma: multi-center real world experiences in China

被引：0
|
作者：
Zhuang, Zhe [1 ]
Shi, Lei [2 ]
Tian, Ying [3 ]
Zou, Dongmei [4 ]
Feng, Ru [5 ]
Dong, Fei [6 ]
Ma, Yanping [7 ]
Yu, Hong [8 ]
Tian, Wei-wei [9 ]
Liu, Shuangjiao [1 ]
Ma, Liang-Ming [10 ]
Fu, Rong [8 ]
Jing, Hongmei [6 ]
Liu, Hui
Sun, Wanling [4 ]
Chen, Wenming [3 ]
Wu, Yin [3 ]
Bao, Li [2 ]
Zhuang, Junling [1 ]
机构：
[1] Chinese Acad Med Sci, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China
[3] Capital Med Univ, Dept Hematol, Beijing Chao Yang Hosp, Beijing, Peoples R China
[4] Capital Med Univ, Dept Hematol, Xuanwu Hosp, Beijing, Peoples R China
[5] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Dept Hematol, Beijing, Peoples R China
[6] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China
[7] Shanxi Med Univ, Dept Hematol, Hosp 2, Taiyuan, Peoples R China
[8] Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin, Peoples R China
[9] Shanxi Med Univ, Dept Hematol, Shanxi Bethune Hosp, Taiyuan, Peoples R China
[10] Shanxi Med Univ, Hosp 2, Dept Hematol, Taiyuan, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-141
引用
收藏
页码：S112 / S113
页数：2
相关论文
共 50 条
  • [41] First-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) for non-transplant eligible symptomatic multiple myeloma patients
    Knauf, W.
    Dingeldein, G.
    Schlag, R.
    Welslau, M.
    Kunz, C.
    Moehler, T.
    Habermehl, C.
    Goldschmidt, H.
    Raab, M-S
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 188 - 188
  • [42] Lenalidomide maintenance in R2-ISS stratified multiple myeloma patients - real world evidence
    Radocha, Jakub
    Jungova, Alexandra
    Pour, Ludek
    Spicka, Ivan
    Minarik, Jiri
    Jelinek, Tomas
    Jindra, Pavel
    Stork, Martin
    Pika, Tomas
    Sedlak, Frantisek
    Popkova, Tereza
    Novakova, Denisa
    Sykora, Michal
    Pavlicek, Petr
    Heindorfer, Adriana
    Wrobel, Marek
    Gregora, Evzen
    Mikula, Peter
    Obernauerova, Jarmila
    Ullrychova, Jana
    Stejskal, Lukas
    Kessler, Petr
    Maisnar, Vladimir
    Hajek, Roman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S122 - S123
  • [43] Real world health and economic outcomes in patients with non-stem cell transplant (NSCT) multiple myeloma initially treated with lenalidomide and/or bortezomib-based regimens.
    Parikh, Kejal
    Abouzaid, Safiya
    Chen, Chi-Chang
    McGuiness, Catherine Balderston
    Wade, Rolin L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Real-world Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma
    Hungria, Vania T. M.
    Moura, Fernanda Lemos
    Soares, Paulo
    Lima, Juliana Souza
    Ricci, Lisa Aquaroni
    Nucci, Fabio Moore
    Oliveira Ribeiro, Eduardo Flavio
    Crusoe, Edvan de Queiroz
    Lima, Marinus de Moraes
    Pessoa de Magalhaes Filho, Roberto Jose
    Arrais-Rodrigues, Celso
    Bhaumik, Amitabha
    Parekh, Trilok
    Borgsten, Fredrik
    Carson, Robin
    Trufelli, Damila C.
    Costa, Abel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S230 - S230
  • [45] Bayesian Network Meta-Analysis (NMA): Safety of Bortezomib, Thalidomide or Lenalidomide Containing Regimens for Transplant Ineligible Multiple Myeloma (MM) Patients
    Satta, Toshihisa
    Yamaguchi, Norihiro
    Malone, Adriana
    Talcott, James
    Chari, Ajai
    BLOOD, 2015, 126 (23)
  • [46] Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China
    Zhang, Fujing
    Wang, Wei
    Wang, Hua
    Wang, Wei
    Liu, Aijun
    Tian, Weiwei
    Qin, Xiaoqi
    Xia, Zhongjun
    Zhuang, Junling
    BLOOD, 2024, 144 : 6985 - 6986
  • [47] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
    Mehra, Maneesha
    Cote, Sarah
    Kampfenkel, Tobias
    Nair, Sandhya
    BLOOD, 2019, 134
  • [48] Thalidomide and Dexamethasone Maintenance after Autologous Stem Cell Transplantation in Newly Diagnosed Korean Multiple Myeloma Patients: A Prospective Multi-Center Study in Asia
    Kim, Sang-A
    Yoon, Sung-Soo
    Koh, Youngil
    Shin, Dong-Yeop
    Kim, Jin Seok
    Kim, Kihyun
    Min, Chang-Ki
    Eom, Hyeon-Seok
    Lee, Je-Jung
    Lee, Jeong-Ok
    Bang, Soo-Mee
    BLOOD, 2017, 130
  • [49] A CANADIAN COST ANALYSIS COMPARING THE USE OF BORTEZOMIB OR LENALIDOMIDE AS MAINTENANCE THERAPIES IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
    LeBlanc, R.
    Tay, J.
    Hollmann, S.
    Shustik, J.
    VALUE IN HEALTH, 2014, 17 (03) : A77 - A77
  • [50] A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma
    Kotb, Rami
    Gul, Engin
    Reece, Donna E.
    BLOOD, 2021, 138
12345